CJC-1295 DAC 5mg: Long-Acting GHRH Analogue

CJC-1295 DAC is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), also known as growth hormone-releasing factor (GRF). It consists of a modified 29-amino-acid chain designed to mimic the body’s natural GHRH while resisting enzymatic breakdown. The “DAC” stands for Drug Affinity Complex, a chemical addition (specifically, N-ε-maleimidopropionyl-Lysine attached to the C-terminus) that binds to albumin in the bloodstream. This binding extends the peptide’s half-life, allowing for prolonged stimulation of growth hormone (GH) release from the pituitary gland.

Scientific Background

Native GHRH is a 44-amino-acid peptide responsible for stimulating pituitary release of growth hormone (GH).
CJC-1295 with DAC is designed to:

• Bind to albumin

• Resist enzymatic degradation

• Maintain sustained GH secretory profiles

• Extend biological activity from minutes → days

In preclinical and laboratory settings, CJC-1295 with DAC has been observed to:

• Enhance pulsatile GH release

• Increase IGF-1 signaling pathways

• Support endocrine research models

• Provide long-duration receptor activation for in-vitro GH axis studies

Its long-lasting nature differentiates it from shorter GHRH analogues such as GRF 1-29 or CJC-1295 without DAC.

Research Areas of Interest

All information below is strictly intended for scientific, laboratory, and in-vitro research only.

1. Growth Hormone Signaling Models

CJC-1295 with DAC is used to study:

• GH secretion patterns

• Pituitary responsiveness

• Interaction with GHRPs (e.g., Ipamorelin, GHRP-2, Hexarelin)

• Endocrine feedback mechanisms

2. IGF-1 & Cellular Growth Pathways

Experimental systems examine:

• IGF-1 expression changes

• Downstream metabolic signaling

• GH/IGF-1 axis dynamics

3. Regeneration & Repair Models

Research explores potential roles in:

• Cell proliferation

• Tissue remodeling

• Recovery-related molecular cascades

4. Endocrine System Studies

CJC-1295 with DAC is frequently used in models involving:

• Hypothalamic–pituitary axis signaling

• GH pulse frequency and amplitude

• Long-duration endocrine pathway activation

5. Comparative Studies

CJC-1295 with DAC is often compared to:

• CJC-1295 without DAC (Mod GRF 1-29)

• Sermorelin

• Ipamorelin

• GHRP-2 / GHRP-6

All findings are from preclinical and in-vitro models only.

Molecular Profile

• Peptide: CJC-1295 with DAC

• Type: Long-acting GHRH analogue

• Sequence Length: 30 amino acids (modified)

• Complex: Drug Affinity Complex (DAC) for extended half-life

• Form: Lyophilized powder

• Purity: ≥ 98% (HPLC tested)

CJC-1295 with DAC includes engineered substitutions and a DAC attachment for albumin binding. Exact proprietary modifications may vary by manufacturer.

Storage & Stability

• Store lyophilized peptide at –20°C

• Protect from heat, moisture, and light

• Reconstituted peptide should be used promptly or stored per laboratory protocol

• Avoid repeated freeze–thaw cycles

  Each 3ml vial is formulated with 5mg of highly purified (>99%) lyophilized CJC 1295 With DAC, produced in sterile environments that meet research-grade standards. Prime Peptides validates every batch through third-party laboratory testing to ensure exact molecular composition, stable peptide structure, and consistent results suitable for a wide range of experimental designs.